Agios Pharmaceuticals (NASDAQ:AGIO) Coverage Initiated at HC Wainwright

Equities researchers at HC Wainwright initiated coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $58.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 64.70% from the company’s current price.

A number of other analysts have also recently commented on AGIO. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Finally, Scotiabank increased their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Trading Up 4.3 %

Agios Pharmaceuticals stock opened at $35.22 on Monday. The company has a market cap of $2.02 billion, a PE ratio of 3.11 and a beta of 0.88. The company’s 50-day moving average is $34.29 and its two-hundred day moving average is $43.03. Agios Pharmaceuticals has a 1 year low of $26.66 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Research analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Venturi Wealth Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. GF Fund Management CO. LTD. bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth about $39,000. Wingate Wealth Advisors Inc. acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $53,000. Sterling Capital Management LLC raised its holdings in Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 1,587 shares during the last quarter. Finally, KBC Group NV boosted its position in Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 611 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.